IE913426A1 - Hybrid growth factors - Google Patents

Hybrid growth factors

Info

Publication number: IE913426A1
Authority: IE; Ireland
Prior art keywords: amino acid; molecule; recombinant; hematopoietic molecule; hematopoietic
Prior art date: 1990-09-28

Application number

IE342691A

Other languages

English (en)

Original Assignee

Ortho Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-28

Filing date

1991-09-27

Publication date

1992-04-08

1991-09-27 Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp

1992-04-08 Publication of IE913426A1 publication Critical patent/IE913426A1/en

Links

239000003102 growth factor Substances 0.000 title description 4
230000003394 haemopoietic effect Effects 0.000 claims abstract description 85
230000004069 differentiation Effects 0.000 claims abstract description 22
230000000694 effects Effects 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
108020004707 nucleic acids Proteins 0.000 claims abstract description 9
102000039446 nucleic acids Human genes 0.000 claims abstract description 9
150000007523 nucleic acids Chemical class 0.000 claims abstract description 9
108010002386 Interleukin-3 Proteins 0.000 claims description 59
102000000646 Interleukin-3 Human genes 0.000 claims description 56
210000004027 cell Anatomy 0.000 claims description 48
125000003275 alpha amino acid group Chemical group 0.000 claims description 32
150000001413 amino acids Chemical class 0.000 claims description 30
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 19
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 18
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 5
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
102000055276 human IL3 Human genes 0.000 claims description 5
239000013598 vector Substances 0.000 claims description 5
230000011132 hemopoiesis Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000013604 expression vector Substances 0.000 claims description 3
210000004962 mammalian cell Anatomy 0.000 claims description 3
108010002616 Interleukin-5 Proteins 0.000 claims description 2
102000000743 Interleukin-5 Human genes 0.000 claims description 2
125000000539 amino acid group Chemical group 0.000 claims description 2
230000001737 promoting effect Effects 0.000 claims description 2
238000012258 culturing Methods 0.000 claims 1
101150002621 EPO gene Proteins 0.000 description 55
229940076264 interleukin-3 Drugs 0.000 description 53
108090000623 proteins and genes Proteins 0.000 description 31
108091034117 Oligonucleotide Proteins 0.000 description 19
239000013612 plasmid Substances 0.000 description 18
239000012634 fragment Substances 0.000 description 13
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
108020004705 Codon Proteins 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
102000001554 Hemoglobins Human genes 0.000 description 8
108010054147 Hemoglobins Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
SXTAYKAGBXMACB-UHFFFAOYSA-N methionine S-imide-S-oxide Natural products CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
241001529936 Murinae Species 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
239000003636 conditioned culture medium Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000007017 scission Effects 0.000 description 5
238000001890 transfection Methods 0.000 description 5
238000003556 assay Methods 0.000 description 4
230000035800 maturation Effects 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
241000283707 Capra Species 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
108020002326 glutamine synthetase Proteins 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000000925 erythroid effect Effects 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
102000018146 globin Human genes 0.000 description 2
108060003196 globin Proteins 0.000 description 2
102000005396 glutamine synthetase Human genes 0.000 description 2
102000044890 human EPO Human genes 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
229960002749 aminolevulinic acid Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
229940025294 hemin Drugs 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
-1 i.e. Proteins 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000001325 yolk sac Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Enzymes And Modification Thereof (AREA)

IE342691A 1990-09-28 1991-09-27 Hybrid growth factors IE913426A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US58995890A	1990-09-28	1990-09-28

Publications (1)

Publication Number	Publication Date
IE913426A1 true IE913426A1 (en)	1992-04-08

Family

ID=24360286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE342691A IE913426A1 (en)	1990-09-28	1991-09-27	Hybrid growth factors

Country Status (8)

Country	Link
EP (1)	EP0503050A4 (fr)
JP (1)	JPH05502463A (fr)
AU (2)	AU8735991A (fr)
CA (1)	CA2069746A1 (fr)
IE (1)	IE913426A1 (fr)
PT (1)	PT99107A (fr)
WO (1)	WO1992006116A1 (fr)
ZA (1)	ZA917766B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5718893A (en) *	1984-04-15	1998-02-17	Foster; Preston F.	Use of G-CSF to reduce acute rejection
WO1992004455A1 (fr) *	1990-08-29	1992-03-19	Genetics Institute, Inc.	Stimulateurs d'hematopoiese multidomaine
US5738849A (en) *	1992-11-24	1998-04-14	G. D. Searle & Co.	Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6153183A (en)	1992-11-24	2000-11-28	G. D. Searle & Company	Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
AU690088B2 (en) *	1992-11-24	1998-04-23	G.D. Searle & Co.	Interleukin-3 (IL-3) multiple mutation polypeptides
US6057133A (en) *	1992-11-24	2000-05-02	G. D. Searle	Multivariant human IL-3 fusion proteins and their recombinant production
US5501962A (en) *	1993-06-21	1996-03-26	G. D. Searle & Co.	Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
WO1995028427A1 (fr) *	1994-04-15	1995-10-26	Imclone Systems Incorporated	Lymphokine chimere composee de l'interleukine 3 et d'une muteine de l'interleukine 6
US5536495A (en) *	1994-04-15	1996-07-16	Foster; Preston F.	Use of G-CSF to reduce acute rejection
ITFI940106A1 (it) *	1994-05-27	1995-11-27	Menarini Ricerche Sud Spa	Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
IT1271688B (it) *	1994-08-04	1997-06-04	Menarini Ricerche Sud Spa	Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
DE69636714T2 (de) *	1995-04-26	2007-10-18	Kyowa Hakko Kogyo Co., Ltd.	G-CSF TPO Fusionsproteine
US6066318A (en)	1995-10-05	2000-05-23	G.D. Searle & Co.	Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
IL129028A0 (en) *	1996-09-20	2000-02-17	Ortho Mcneil Pharm Inc	Method for in vitro determination of erythropoietin bioactivity
WO1998018926A1 (fr) *	1996-10-25	1998-05-07	G.D. Searle & Co.	Agonistes de recepteurs d'erythropoietine permutes de maniere circulaire
US6967092B1 (en)	1996-10-25	2005-11-22	Mc Kearn John P	Multi-functional chimeric hematopoietic receptor agonists
NZ335382A (en) *	1996-10-25	2001-03-30	Searle & Co	Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases
US6165476A (en) *	1997-07-10	2000-12-26	Beth Israel Deaconess Medical Center	Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en)	1997-07-10	2001-02-13	Beth Israel Deaconess Medical Center	DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
EP0902085B1 (fr) *	1997-09-01	2003-12-03	Aventis Pharma Deutschland GmbH	Erythropoiétine humaine recombinante caractérisée par une glycosylation avantageuse
AU2866599A (en) *	1998-02-17	1999-08-30	Hyseq, Inc.	A novel interleukin-3 and uses thereof
BR9917606A (pt) *	1998-11-06	2002-12-31	Bio Sidus S A	Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
KR20050121762A (ko)	2000-05-15	2005-12-27	에프. 호프만-라 로슈 아게	신규한 약학 조성물
US7220407B2 (en)	2003-10-27	2007-05-22	Amgen Inc.	G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
ATE544463T1 (de)	2004-11-05	2012-02-15	Univ Northwestern	Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
EP2542574B1 (fr)	2010-03-04	2017-08-09	Pfenex Inc.	Procédé pour la production de la protéine interféron recombinante soluble sans dénaturation
PL2552949T3 (pl)	2010-04-01	2017-01-31	Pfenex Inc.	Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas
SG11201500414SA (en)	2012-07-31	2015-04-29	Asahi Kasei E Materials Corp	Epoxy resin composition, epoxy resin, and cured product
LT6161B (lt)	2013-09-27	2015-06-25	Uab Profarma	Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8407097A1 (es) *	1982-05-12	1984-08-16	Harvard College	Un procedimiento para obtener una proteina hibrida.
US4935352A (en) *	1985-10-21	1990-06-19	Takeda Chemical Industries, Ltd.	Expression vector for animal cell line and use thereof
US4935233A (en) *	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
DE3751664T2 (de) *	1986-08-01	1996-06-05	Commw Scient Ind Res Org	Rekombinanter impfstoff
EP0425536A4 (en) *	1988-07-20	1992-01-02	Immunex Corporation	Nonglycosylated human interleukin-3 compositions
US5166322A (en) *	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1991001004A1 (fr) *	1989-07-06	1991-01-24	Seragen, Inc.	Molecules hybrides
ES2055445T3 (es) *	1989-08-22	1994-08-16	Immunex Corp	Proteinas de fusion que comprenden gm-csf e il-3.
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
IL96477A0 (en) *	1989-12-01	1991-08-16	Amgen Inc	Megakaryocyte production
WO1992004455A1 (fr) *	1990-08-29	1992-03-19	Genetics Institute, Inc.	Stimulateurs d'hematopoiese multidomaine

1991
- 1991-09-26 WO PCT/US1991/007053 patent/WO1992006116A1/fr not_active Application Discontinuation
- 1991-09-26 JP JP3517013A patent/JPH05502463A/ja active Pending
- 1991-09-26 AU AU87359/91A patent/AU8735991A/en not_active Abandoned
- 1991-09-26 EP EP19910918221 patent/EP0503050A4/en not_active Withdrawn
- 1991-09-26 CA CA002069746A patent/CA2069746A1/fr not_active Abandoned
- 1991-09-27 ZA ZA917766A patent/ZA917766B/xx unknown
- 1991-09-27 PT PT99107A patent/PT99107A/pt not_active Application Discontinuation
- 1991-09-27 IE IE342691A patent/IE913426A1/en not_active Application Discontinuation
1995
- 1995-02-06 AU AU11576/95A patent/AU1157695A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1992006116A1 (fr)	1992-04-16
EP0503050A4 (en)	1994-07-06
CA2069746A1 (fr)	1992-03-29
AU1157695A (en)	1995-04-13
ZA917766B (en)	1993-03-29
EP0503050A1 (fr)	1992-09-16
AU8735991A (en)	1992-04-28
PT99107A (pt)	1992-08-31
JPH05502463A (ja)	1993-04-28

Publication	Publication Date	Title
IE913426A1 (en)	1992-04-08	Hybrid growth factors
JP3276933B2 (ja)	2002-04-22	エリスロポエチン活性を有する糖蛋白質の製造方法
EP1961425B1 (fr)	2017-07-19	Procédés et analogues de l'érytropoïétine pour la prévention et le traitement de l'anémie
EP0285448B1 (fr)	1994-03-16	Facteur d'inhibition de la leucémie
SA92130214B1 (ar)	2004-02-10	انتاج اريثروبوينين Erythropoietin
US20080108560A1 (en)	2008-05-08	Heterologous G-Csf Fusion Proteins
JP2002514887A (ja)	2002-05-21	トロンボポイエチンポリペプチドの分泌方法
FI103987B (fi)	1999-10-29	Interleukiini-7
US5545536A (en)	1996-08-13	Colony-stimulating factor derivatives
JPH04506342A (ja)	1992-11-05	非グリコシル化ヒトインターロイキン―３類似蛋白質
JPH06133793A (ja)	1994-05-17	ミュレル管抑制物質様ポリペプチドおよびその製造方法
JPH11500308A (ja)	1999-01-12	新規ｃ−ＭＰＬリガンド
JPH10500579A (ja)	1998-01-20	増血刺激作用を有する式ｇｍ−ｃｓｆ−ｌ−ｅｐｏまたはｅｐｏ−ｌ−ｇｍ−ｃｓｆのハイブリッド分子
Ichihara et al.	1995	Impaired interleukin‐3 (IL‐3) response of the A/J mouse is caused by a branch point deletion in the IL‐3 receptor alpha subunit gene.
AU725547B2 (en)	2000-10-12	Multi-functional chimeric hematopoietic receptor agonists
JPH0657156B2 (ja)	1994-08-03	新糖蛋白質の製法
AU751498B2 (en)	2002-08-15	flt3 ligand chimeric proteins
JPH05103675A (ja)	1993-04-27	ヒト神経成長因子２の製造法
JPH02195887A (ja)	1990-08-02	ヒトインターロイキン２活性をもつポリペプチドをコードする遺伝子
KR910005624B1 (ko)	1991-08-01	인체 과립성 백혈구의 콜로니 자극 인자 활성을 갖는 당단백질의 제조방법
JP3580836B2 (ja)	2004-10-27	好中球減少症治療剤
JPH0361494A (ja)	1991-03-18	ムテイン，ｄｎａおよびその用途
WO1995023861A1 (fr)	1995-09-08	MEGACARYOPOIETINE HUMAINE ET ISOLEMENT DE CELLE-CI, CLONAGE D'ADNc, ET PREPARATION DE LA PROTEINE RECOMBINEE
CZ346799A3 (cs)	2000-03-15	Chimérické proteiny jako flt3 ligandy
JPH0482900A (ja)	1992-03-16	新規ｍ―ｃｓｆ及びその製造方法

Legal Events

Date	Code	Title	Description
2002-11-27	FC9A	Application refused sect. 31(1)